FDA WARNING_LETTER - onlineotcmeds.com - October 15, 2025

On October 15, 2025, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to onlineotcmeds.com, citing the unlawful sale of unapproved and misbranded drugs to U.S. consumers via its website. The FDA"s review revealed that onlineotcmeds.com introduces several controlled substances into interstate commerce, including unapproved and misbranded opioids, benzodiazepines, and Schedule II stimulants. The letter highlights significant public health risks associated with these sales, particularly given the ongoing opioid epidemic and the potential for abuse and severe medical outcomes when benzodiazepines and stimulants are misused, especially in combination with other substances. The FDA emphasizes that unapproved drugs lack the necessary assurances of safety and effectiveness, potentially being contaminated, counterfeit, or containing incorrect active ingredients. These actions violate multiple sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which prohibits the introduction of unapproved new drugs and misbranded drugs into interstate commerce. Specifically, onlineotcmeds.com was found to be selling products like Fentanyl Patches, Hydromorphone HCl (Dilaudid), and Oxymorphone HCl (Opana) without FDA approval. The FDA mandates that onlineotcmeds.com immediately cease offering any unapproved and misbranded drugs for sale to U.S. consumers to protect public health.